Quantitative proteomic profiling of breast cancers using a multiplexed microfluidic platform for immunohistochemistry and immunocytochemistry

Biomaterials

Volumn 32, Issue 5, 2011, Pages 1396-1403

  Kim, Minseok S ^a   Kwon, Seyong ^a   Kim, Taemin ^a   Lee, Eun Sook ^b   Park, Je Kyun ^a  

^a Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Fluorescence; Immunochemistry; In vitro test; Microfluidics; Micropatterning; Polydimethylsiloxane

Indexed keywords

BIOLOGICAL SPECIMENS; BREAST CANCER; BREAST CANCER CELLS; CANCER THERAPY; CELL LINES; CELL MARKERS; CLINICAL SAMPLES; EPIDERMAL GROWTH FACTOR RECEPTORS; ESTROGEN RECEPTOR; EXPRESSION LEVELS; HISTOPATHOLOGICAL DIAGNOSIS; HUMAN BREAST CANCER; IMMUNOCHEMISTRY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMICAL STAINING; IMMUNOHISTOCHEMISTRY; IN-VITRO TESTS; MICRO FLUIDIC SYSTEM; MICRO PATTERNING; MICRO-FLUIDIC DEVICES; MICROFLUIDIC PLATFORMS; PROTEOMIC PROFILING; TIME CONSUMPTION;

BIOCHEMISTRY; BIOMARKERS; CELL CULTURE; FLUIDIC DEVICES; FLUORESCENCE; MULTIPLEXING; SILICONES;

MICROFLUIDICS;

CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P63;

ADENOCARCINOMA; ARTICLE; BREAST CANCER; CANCER CELL; CANCER TISSUE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MICROFLUIDIC ANALYSIS; MYOEPITHELIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS;

BREAST NEOPLASMS; CELL LINE, TUMOR; DIMETHYLPOLYSILOXANES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICROFLUIDICS; PROTEOMICS;

EID: 78649753915     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.040     Document Type: Article

References (32)

1. Lakhani S.R., Ashworth A. Microarray and histopathological analysis of tumours: the future and the past?. Nat Rev Cancer 2001, 1:151-157.
2. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006, 354:2463-2472.
3. Sotiriou C., Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 2007, 7:545-553.
4. Stingl J., Caldas C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer 2007, 7:791-799.
5. Ludwig J.A., Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005, 5:845-856.
6. van't Veer L.J. Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008, 452:564-570.
7. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
8. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
9. Kao J., Salari K., Bocanegra M., Choi Y.L., Girard L., Gandhi J., et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 2009, 4:e6146.
10. Wulfkuhle J.D., Liotta L.A., Petricoin E.F. Proteomic applications for the early detection of cancer. Nat Rev Cancer 2003, 3:267-275.
11. Charafe-Jauffret E., Ginestier C., Monville F., Finetti P., Adelaide J., Cervera N., et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 2006, 25:2273-2284.
12. Makretsov N.A., Huntsman D.G., Nielsen T.O., Yorida E., Peacock M., Cheang M.C., et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 2004, 10:6143-6151.
13. Jacquemier J., Ginestier C., Rougemont J., Bardou V.J., Charafe-Jauffret E., Geneix J., et al. Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. Cancer Res 2005, 65:767-779.
14. Ginestier C., Charafe-Jauffret E., Bertucci F., Eisinger F., Geneix J., Bechlian D., et al. Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. Am J Pathol 2002, 161:1223-1233.
15. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
16. Charpin C., Secq V., Giusiano S., Carpentier S., Andrac L., Lavaut M.N., et al. A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays. Int J Cancer 2009, 124:2124-2134.
17. Vargo-Gogola T., Rosen J.M. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7:659-672.
18. Lacroix M., Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 2004, 83:249-289.
19. Shah R.K., London A.L. Laminar flow forced convection in ducts: a source book for compact heat exchanger analytical data 1978, Academic Press, New York.
20. Vestad T., Marr D.W.M. Flow resistance for microfluidic logic operations. Appl Phys Lett 2004, 84:5074-5075.
21. Kim M.S., Kim T., Kong S.Y., Kwon S., Bae C.Y., Choi J., et al. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PLoS One 2010, 5:e10441.
22. Laakso M., Loman N., Borg A., Isola J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 2005, 18:1321-1328.
23. Chu P.G., Weiss L.M. Expression of cytokeratin 5/6 in epithelial neoplasms: an immunohistochemical study of 509 cases. Mod Pathol 2002, 15:6-10.
24. Narayanan K., Jaramillo A., Benshoff N.D., Campbell L.G., Fleming T.P., Dietz J.R., et al. Response of established human breast tumors to vaccination with mammaglobin-A cDNA. J Natl Cancer Inst 2004, 96:1388-1396.
25. Koker M.M., Kleer C.G. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004, 28:1506-1512.
26. Banerjee S., Dhar G., Haque I., Kambhampati S., Mehta S., Sengupta K., et al. CCN5/WISP-2 expression in breast adenocarcinoma is associated with less frequent progression of the disease and suppresses the invasive phenotypes of tumor cells. Cancer Res 2008, 68:7606-7612.
27. Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007, 1:84-96.
28. Gazdar A.F., Kurvari V., Virmani A., Gollahon L., Sakaguchi M., Westerfield M., et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 1998, 78:766-774.
29. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527.
30. Shoker B.S., Jarvis C., Clarke R.B., Anderson E., Hewlett J., Davies M.P., et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 1999, 155:1811-1815.
31. Ewan K.B., Oketch-Rabah H.A., Ravani S.A., Shyamala G., Moses H.L., Barcellos-Hoff M.H. Proliferation of estrogen receptor-alpha-positive mammary epithelial cells is restrained by transforming growth factor-beta1 in adult mice. Am J Pathol 2005, 167:409-417.
32. Badve S., Nakshatri H. Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 2009, 62:6-12.